Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineImpact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccineAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesSynthetic DNA vaccine strategies against persistent viral infectionsSingle-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 virusesSafety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adultsA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesSafety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetBovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.Phase 1 study of pandemic H1 DNA vaccine in healthy adultsObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Vaccine design for CD8 T lymphocyte responsesControl of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.Human immunodeficiency virus vaccine trialsEfficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Full genome sequence analysis of a novel adenovirus of rhesus macaque origin indicates a new simian adenovirus type and species.Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationFusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesHIV-1 vaccine development after STEP.Novel directions in HIV-1 vaccines revealed from clinical trialsEfficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challengeNeutralizing antibody responses to enterovirus and adenovirus in healthy adults in ChinaSafety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidatePrime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaquesTrivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.
P2860
Q21092234-996F003D-434C-4901-BBE4-02B958E460ECQ21134724-87A96834-DB45-4D6E-A1FF-4EA06E4EC60EQ27013568-BA77F4B5-6A58-40C7-876E-54CD14008FA2Q27016078-BD3051F8-C3B2-4CB1-9721-E36446B8F48CQ27318575-93FD2799-8A8B-4134-B0B8-495074B8006CQ28740321-425799A9-0FB7-4B4B-927D-796104BCA70DQ28741673-51ECC133-7E2C-4A00-A313-1CCBA825BFD9Q28749120-B6B57D41-FA5D-4313-AE0E-3F1C85EA1CB9Q28749224-2321F9CE-973A-481D-8FD1-F19CC8E3CCFEQ28972526-E0AB8955-BA6D-4109-A5C5-EBC684243EE9Q30226988-1A768320-8D6D-4062-B6B7-E868E3D4CF31Q30227194-4B8DB674-5A31-4382-9076-B82E8AE71A32Q30229074-B12B6582-F366-49B2-93D8-EE47BFBE3635Q30365380-C940294F-5B72-44B8-9F19-DDA47DF742F1Q30373824-2E79AD1A-CF73-4F41-853B-50ABC17E8BA7Q30378897-00BF0D80-C4CB-4B5D-95FE-87E0BFF4E36DQ30379200-C4C03DE6-CEC1-42A7-88C9-6E6435556FC5Q30382097-1FD01171-0C76-4636-A7A4-A490E9515DCEQ30410411-7048E575-9D69-4FD4-8F88-63000E356C47Q30411492-FAC96E23-A970-4E76-B141-E7781A033403Q30422006-CA6AE13D-2C45-4E61-B1B6-1F37DEBD7B59Q30424366-C43B8028-2C6F-4A6F-99B1-0ED73FA869E9Q30578618-8249260F-B310-4BD2-B987-41D7E5D0A724Q30881414-5FBE8D21-4F94-49FF-95D4-4333214C3C92Q33380283-AE2C1245-E58F-407E-9A35-E9D818D98FFAQ33558605-5373B2AC-50AB-4D1B-9365-9E4DFC2DBBF2Q33586992-D8B2622D-C4E9-4FA7-A709-E01B59DD75A7Q33601808-EC31C391-27EA-4D8F-8049-24FB77397F6FQ33611719-9CE77C8A-14DE-40FB-BEEB-526E80057B23Q33614461-8BA9B8FB-77C5-4F99-B9D1-3621D70D591EQ33642318-22B0832C-DE89-4258-A1B5-66175E325E80Q33645528-480C5403-A4F4-47B6-93A7-A3DA9146621EQ33676444-DB05103C-D750-4C2E-819C-F021CB578C7AQ33733003-C8E415BD-F770-4C6E-8D28-89E6CD3D86C9Q33737476-EBFD3785-63FB-400C-BE53-CB26961E9A59Q33749950-54216DCF-64CC-475C-BF96-29DFD4A85C6EQ33829574-0CF9F47D-8786-4EFA-A825-7F6FB7A4D3D3Q33839468-2D35462D-C444-4663-A478-070FB88D60BCQ33868760-509B3716-C1F6-4350-BA65-8992CA8C882DQ33896435-E5DC42A7-E81F-4272-BF5F-CA952E3E276C
P2860
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@ast
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@en
type
label
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@ast
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@en
prefLabel
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@ast
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@en
P2093
P2860
P50
P356
P1476
Phase 1 safety and immunogenic ...... recombinant adenovirus vector
@en
P2093
Andrew T Catanzaro
Bimal K Chakrabarti
Bryan T Butman
C Richter King
Charla A Andrews
Jason G D Gall
Julie E Martin
Laura Novik
Mario Roederer
P2860
P304
P356
10.1086/509258
P407
P577
2006-11-08T00:00:00Z